Drug Trial News

RSS

Multiple HIV-1 variants at the beginning of infection impact viral load setpoints

HIV-1 infection with multiple founder variants points to poorer clinical outcomes than infection with a single variant, according to a paper published today in the journal Nature Medicine.

1 Sep 2015

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA).

31 Aug 2015

Resverlogix presents new data on RVX-208 orally active BET inhibitor at ESC Congress 2015

Resverlogix Corp. is pleased to announce that Dr. Norman Wong, chief scientific officer of Resverlogix Corp. presented new data at the European Society of Cardiology (ESC) Congress 2015 in a poster presentation titled: "RVX-208, an orally active BET inhibitor, lowers CVD risk by activities beyond raising ApoA-I/HDL."

31 Aug 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has completed enrollment of the additional subjects, as directed by the Data Review Committee (DRC) earlier this year, into the company's Phase 2 study for SGX942.

31 Aug 2015

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Ascletis today announced it received the approval from the Taiwan Food and Drug Administration (TFDA) to start phase II clinical trial for its all-oral interferon (IFN)-free regimen to treat chronic hepatitis C (CHC).

31 Aug 2015

PATHWAY 3 study: Half dose combination of common diuretics reduces blood pressure

The combination of two commonly used diuretics, each at half dose, can significantly reduce blood pressure without the side-effects caused by full doses of either alone, researchers from the PATHWAY 3 study have found.

31 Aug 2015

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.

31 Aug 2015

Phase III trial results show cariprazine effective in treating negative symptoms associated with schizophrenia

Results of a clinical trial seem to show the first effective treatment for the negative symptoms - withdrawal, lack of emotion, and apathy - associated with schizophrenia.

31 Aug 2015

Passport Health participates in clinical study to test effects of oral typhoid vaccination

Passport Health, in partnership with vaccine manufacturer PaxVax, Inc. is participating in a clinical study to test the effects of the oral typhoid vaccination, Vivotif (Typhoid Vaccine Live Oral Ty21a). The study will look at the side effects that could occur when taking Vivotif across the range of approved potencies.

28 Aug 2015

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.

27 Aug 2015

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with previously treated advanced or metastatic non-small cell lung cancer ("NSCLC") (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.

26 Aug 2015

Omega-3 supplements fail to slow cognitive decline in older persons, NIH clinical study shows

While some research suggests that a diet high in omega-3 fatty acids can protect brain health, a large clinical trial by researchers at the National Institutes of Health found that omega-3 supplements did not slow cognitive decline in older persons. With 4,000 patients followed over a five-year period, the study is one of the largest and longest of its kind.

26 Aug 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London.

26 Aug 2015

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

Clementia Pharmaceuticals, Inc. today announced the initiation of enrollment of children as young as 6 years old in the company's ongoing Phase 2 study of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP).

26 Aug 2015

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK), efficacy, and safety of the company's recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP) for on-demand treatment in patients with congenital hemophilia A or B who have developed an inhibitor to factor VIII or factor IX replacement therapy.

26 Aug 2015

Better drug design may soon be aided by Scripps scientists’ discoveries

For the first time, they have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output. These new findings could aid future drug design by giving scientists an edge in fine tuning the signal between these partnered proteins—and the drug’s course of action.

25 Aug 2015

BET inhibitors can cause molecular changes in neurons, lead to memory loss in mice

Cancer researchers are constantly in search of more-effective and less-toxic approaches to stopping the disease, and have recently launched clinical trials testing a new class of drugs called BET inhibitors. These therapies act on a group of proteins that help regulate the expression of many genes, some of which play a role in cancer.

25 Aug 2015

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today enrollment has commenced in its Phase II(b) SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.

23 Aug 2015

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol.

23 Aug 2015

Researchers find effectiveness of ramelteon for treatment of sleep disturbances after TBI

Kessler researchers found preliminary evidence for the effectiveness of ramelteon for the treatment of sleep disturbances after traumatic brain injury (TBI). The article, "Archives of Physical Medicine and Rehabilitation on May 28, 2015. Authors are Anthony Lequerica, PhD, and Nancy Chiaravalloti, PhD, of Kessler Foundation, Neil Jasey, MD, of Kessler Institute for Rehabilitation, and Jaclyn Portelli Tremont, MA, of Robert Wood Johnson Medical School, Rutgers University.

21 Aug 2015

Drug Trial News

Multiple HIV-1 variants at the beginning of infection impact viral load setpoints

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Resverlogix presents new data on RVX-208 orally active BET inhibitor at ESC Congress 2015

Soligenix completes enrolment in SGX942 Phase 2 trial for oral mucositis in cancer patients

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

PATHWAY 3 study: Half dose combination of common diuretics reduces blood pressure

ELIXA trial results demonstrate cardiovascular safety of lixisenatide drug

Phase III trial results show cariprazine effective in treating negative symptoms associated with schizophrenia

Passport Health participates in clinical study to test effects of oral typhoid vaccination

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Omega-3 supplements fail to slow cognitive decline in older persons, NIH clinical study shows

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial

First patient enrolled in CSL Behring's rVIIa-FP Phase II/III study to treat patients with hemophilia A or B with inhibitors

Better drug design may soon be aided by Scripps scientists’ discoveries

BET inhibitors can cause molecular changes in neurons, lead to memory loss in mice

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

Researchers find effectiveness of ramelteon for treatment of sleep disturbances after TBI

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

How microRNA is transforming science: From discovery to diagnostics

Latest News